Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas By Ogkologos - October 26, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer A glucometer for cancer: towards a scalable, universal residual disease measurement MOST POPULAR EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate May 4, 2021 A Phase III Study of Spartalizumab in Combination with Dabrafenib and... January 20, 2022 Study Advances Fertility Preservation Approach for Male Cancer Survivors April 24, 2019 EMA Recommends Extension of Therapeutic Indications for Selinexor June 15, 2022 Load more HOT NEWS Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers Do Cancer Survivors Have To Be Positive All the Time? Letting... Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once...
